Key result
Elevated troponin I in acute decompensated diabetes without ACS linked to ~19-fold higher MACE risk.
Why the study?
The impact of cardiac troponin elevation on long-term cardiac outcomes in acute decompensated diabetes without acute coronary syndrome was unexplored.
Does elevated cardiac troponin I predict major cardiovascular events in patients with acute decompensated diabetes without acute coronary syndrome?
Population
264 patients admitted with DKA or HHS without acute coronary syndrome at Temple University Hospital
Comparison
Elevated cardiac troponin I vs normal cardiac enzyme levels
Design
Retrospective cohort analysis
Follow-up
At least 18 months
Authors
Loading...
May inform risk stratification in acute decompensated diabetes; hypothesis-generating and requires prospective validation before changing practice.
Cohort (n=264)
No
Does elevated cardiac troponin I predict major cardiovascular events in patients with acute decompensated diabetes without acute coronary syndrome?
Absolute Event Rate: 33% vs 1.7%
Absolute Risk Reduction: 31.3%
p-value: p=<0.001
Elevated cardiac troponin I in patients with acute decompensated diabetes without ACS is an independent predictor of long-term major cardiovascular events, highlighting a high-risk cohort that may benefit from targeted risk stratification.
Eubanks et al. (2012) conducted a cohort in Acute decompensated diabetes without acute coronary syndrome (n=264). Elevated cardiac troponin I vs. Normal cardiac troponin I was evaluated on Major adverse cardiovascular event (MACE) (p=<0.001). Elevated cardiac troponin I in patients with acute decompensated diabetes without acute coronary syndrome was associated with a significantly higher incidence of major adverse cardiovascular events compared to patients with normal troponin levels (33.0% vs 1.7%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: